VivoSim Labs, Inc. (VIVS)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN Summary
VivoSim Labs, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SE Sima Elimelech Activest Wealth Management | 2 | $2.86 | $2.32 | -$0.54 | -18.88% |
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 2 | $4.48 | $2.32 | -$2.16 | -48.21% |
VivoSim Labs, Inc. (VIVS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has VivoSim Labs, Inc. ever had a stock split?
VivoSim Labs, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Keith E. Murphy CEO | NASDAQ (CM) Exchange | 68620A302 CUSIP |
| US Country | 14 Employees | - Last Dividend | 21 Mar 2025 Last Split | - IPO Date |
Overview
VivoSim Labs, Inc. is a biotechnology enterprise dedicated to the innovation and development of 3D tissues that emulate critical aspects of human diseases. This cutting-edge company is recognized for its advanced 3D human tissue platform, which leverages proprietary NovoGen Bioprinters. These automated systems facilitate the crafting of 3D living tissues composed of mammalian cells, thereby significantly enhancing the scope of research and therapeutic options in the field of medicine. The prominent solutions developed by VivoSim Labs not only include state-of-the-art bioprinting technologies but also cover bio-ink preparations essential for constructing multicellular tissues featuring intricate architectures.
VivoSim Labs' prime candidate, FXR314, is currently undergoing phase 2/3 clinical trials targeted at managing inflammatory bowel disease with a significant emphasis on ulcerative colitis. Additionally, the company has successfully completed phase 1 clinical trials for FXR314 aimed at addressing liver fibrosis, particularly focusing on steatohepatitis. With a strong academic partnership footprint, VivoSim Labs has established research collaborations with distinguished institutions, including the Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia. The firm, which was originally known as Organovo Holdings, Inc., rebranded to VivoSim Labs, Inc. in April 2025 and has been operational since its incorporation in 2007, with its headquarters situated in San Diego, California.
Products and Services
- 3D Human Tissue Platform: This platform comprises advanced technologies to replicate human tissues using 3D bioprinting methods. It helps in creating complex tissue structures that are crucial for studying disease mechanisms and testing therapeutic interventions.
- Proprietary NovoGen Bioprinters: These state-of-the-art automated devices are central to VivoSim's production of 3D living tissues. They enable high-precision fabrication of tissues, utilizing mammalian cells and tailored bio-inks to accurately simulate human biological conditions.
- Bio-inks Preparation Technologies: VivoSim Labs has developed sophisticated technologies for formulating bio-inks that serve as the building blocks for bioprinting multicellular tissues. These bio-inks are designed to support cell viability and functionality, essential for effective tissue engineering.
- FXR314 Drug Development: FXR314 is the lead candidate from VivoSim Labs, aimed at treating inflammatory bowel disease and liver fibrosis. Its clinical trials signify the company’s commitment to providing innovative therapeutic solutions for complex health issues.
- Collaborative Research Initiatives: The company engages in collaborative research with esteemed academic institutions to advance the science of bioprinting and tissue engineering. These partnerships are geared towards enhancing the applications of its technologies in real-world medical challenges.
